SG Americas Securities LLC Boosts Holdings in Repligen Co. (NASDAQ:RGEN)

SG Americas Securities LLC lifted its stake in shares of Repligen Co. (NASDAQ:RGEN) by 131.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,520 shares of the biotechnology company’s stock after acquiring an additional 3,701 shares during the period. SG Americas Securities LLC’s holdings in Repligen were worth $970,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. V Square Quantitative Management LLC raised its position in shares of Repligen by 76.8% in the 4th quarter. V Square Quantitative Management LLC now owns 564 shares of the biotechnology company’s stock worth $101,000 after buying an additional 245 shares during the period. Neo Ivy Capital Management purchased a new position in shares of Repligen in the 4th quarter worth about $164,000. Congress Asset Management Co. MA lifted its stake in shares of Repligen by 220.9% in the 4th quarter. Congress Asset Management Co. MA now owns 76,800 shares of the biotechnology company’s stock valued at $13,809,000 after purchasing an additional 52,868 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Repligen by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 5,078,294 shares of the biotechnology company’s stock worth $913,077,000 after purchasing an additional 33,404 shares during the period. Finally, CWM LLC grew its holdings in shares of Repligen by 19.9% during the 1st quarter. CWM LLC now owns 361 shares of the biotechnology company’s stock worth $66,000 after purchasing an additional 60 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Repligen

In other news, VP Ralf Kuriyel sold 4,465 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $165.67, for a total value of $739,716.55. Following the completion of the sale, the vice president now owns 19,261 shares of the company’s stock, valued at approximately $3,190,969.87. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Anthony Hunt sold 22,191 shares of the firm’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the transaction, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Ralf Kuriyel sold 4,465 shares of Repligen stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $165.67, for a total transaction of $739,716.55. Following the completion of the transaction, the vice president now directly owns 19,261 shares of the company’s stock, valued at approximately $3,190,969.87. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 1.20% of the stock is currently owned by corporate insiders.

Repligen Stock Up 3.2 %

Shares of NASDAQ RGEN opened at $138.82 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65. Repligen Co. has a 1 year low of $110.45 and a 1 year high of $211.13. The stock’s 50-day simple moving average is $147.95 and its 200-day simple moving average is $150.23. The firm has a market cap of $7.76 billion, a price-to-earnings ratio of 555.28, a PEG ratio of 4.05 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.33. The company had revenue of $154.07 million for the quarter, compared to the consensus estimate of $154.11 million. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. Repligen’s revenue for the quarter was down 3.2% compared to the same quarter last year. During the same period in the previous year, the business earned $0.53 EPS. As a group, equities analysts anticipate that Repligen Co. will post 1.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

RGEN has been the topic of a number of recent research reports. Benchmark reaffirmed a “hold” rating on shares of Repligen in a research report on Monday, August 5th. JPMorgan Chase & Co. lifted their target price on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a report on Wednesday, July 31st. Guggenheim started coverage on Repligen in a report on Tuesday, June 18th. They issued a “neutral” rating for the company. Wells Fargo & Company started coverage on Repligen in a research note on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price objective on the stock. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, Repligen currently has an average rating of “Moderate Buy” and an average price target of $190.25.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.